New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
08:22 EDTCGIXCancer Genetics launches genomic test for FL, MCL
Cancer Genetics announced it has received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA for Follicular Lymphoma, or MatBA-FL, and Mantle-Cell Lymphoma, or MatBA-MCL. Both tests further extend the portfolio in hematologic cancers being developed by CGI and both were developed and validated via a research collaboration with Memorial Sloan-Kettering Cancer Center. MatBA-FL and MatBA-MCL assist clinicians in the prognosis of Follicular Lymphoma, or FL, and Mantle-Cell Lymphoma, or MCL. MatBA-FL identifies genomic aberrations that are associated with the high frequency of transformation of FL into Diffuse Large B-Cell Lymphoma, or DLBCL, and shorter overall survival, or OS. MatBA-MCL identifies genomic aberrations that are associated with high frequency of either a leukemic involvement and/or shorter OS. Understanding the potential outcome for the patient is critical in making informed choices about treatment selection, clinical trial involvement and patient management.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
07:22 EDTCGIXAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
07:56 EDTCGIXCancer Genetics receives second patent for FHACT
Cancer Genetics announced that it has received a second U.S. patent covering its proprietary FISH-based HPV-Associated Cancer Test, or FHACT, for cervical cancer detection in patients. FHACT is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. Critically, FHACT can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures.
November 10, 2014
07:58 EDTCGIXCancer Genetics reports adjusted Q3 EPS (41c), consensus (48c)
Reports Q3 revenue $3.22M, consensus $3.18M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use